Literature DB >> 27840961

Inhibition of human colorectal cancer metastasis by notoginsenoside R1, an important compound from Panax notoginseng.

Chang-Yin Lee1, Shu-Ling Hsieh2, Shuchen Hsieh3, Chin-Chung Tsai1, Lan-Chi Hsieh4, Yu-Hao Kuo2, Chih-Chung Wu5.   

Abstract

Panax notoginseng (P. notoginseng) and its components are used as traditional Chinese medicine for cardiovascular disease, although studies concerning the anti-metastatic properties of these compounds are limited. The goal of this study was to investigate the effects of notoginsenoside R1 (NGR1), an important compound derived from P. notoginseng, on the metastasis of human colorectal cancer (CRC). The migratory, invasive, and adhesive abilities of cultured human CRC cells (HCT-116) treated with NGR1 and expression of metastasis‑associated regulatory molecules were assessed. The migratory and invasive abilities of the HCT-116 cells were reduced after treatment with 75, 150 or 300 µM NGR1 for 24 h. When HCT-116 cells were incubated with 150 or 300 µM NGR1 for 24 h, matrix metalloproteinase (MMP)-9 expression was reduced compared with that of the control group. In the adhesion reaction assays, treatment with 150 or 300 µM NGR1 led to significantly decreased adhesion of the HCT-116 cells to endothelial cells (EA.hy926 cells). Levels of integrin-1 protein were significantly decreased in the HCT-116 cells following treatment with 75, 150 or 300 µM NGR1, and levels of E-selectin and intercellular adhesion molecule 1 (ICAM-1) proteins were significantly decreased in the EA.hy926 cells treated with 75, 150 or 300 µM NGR1. Scanning electron microscopy examination indicated that HCT-116 cells treated with lipopolysaccharide (LPS) combined with 300 µM NGR1 exhibited a less flattened and retracted shape compared with cells treated with LPS alone, and this change in shape is characteristic of extravasation. Additionally, the transepithelial electrical resistance of the EA.hy926 endothelial cell monolayer increased after incubation with 150 or 300 µM NGR1 for 24 h. Overall, these results demonstrated the anti-metastatic properties of 150 or 300 µM NGR1, a compound that affects CRC metastasis by inhibiting cell migration, invasion, and adhesion and by regulating expression of metastasis-associated signalling molecules.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27840961     DOI: 10.3892/or.2016.5222

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  11 in total

1.  In Vitro Anti-hepatoma Activities of Notoginsenoside R1 Through Downregulation of Tumor Promoter miR-21.

Authors:  Yuan Li; Zhong Li; Yunhao Jia; Bo Ding; Jinsong Yu
Journal:  Dig Dis Sci       Date:  2019-09-26       Impact factor: 3.199

Review 2.  Anticancer activities of phytoconstituents and their liposomal targeting strategies against tumor cells and the microenvironment.

Authors:  Jing Zhang; Xiang Li; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2020-05-28       Impact factor: 15.470

3.  Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell-Bearing Mice.

Authors:  Hwa Jeong Kang; Jeehye Kim; Seong Hyeok Cho; So-Jung Park; Hwa-Seung Yoo; In-Cheol Kang
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

4.  Effect of NGR1 on the Atopic Dermatitis Model and its Mechanisms.

Authors:  Mingmei Wang; Jianli Ma
Journal:  Open Med (Wars)       Date:  2019-11-10

5.  20(S)-Protopanaxdiol Suppresses the Abnormal Granule-Monocyte Differentiation of Hematopoietic Stem Cells in 4T1 Breast Cancer-Bearing Mouse.

Authors:  Wen-Qin Guo; Ying-Ge Chen; Rong-Zhen Shi; Kai He; Jian-Feng Wang; Jin-Hui Shao; Jian-Bo Wan; Jian-Li Gao
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-03       Impact factor: 2.629

6.  Anti-Cancer Effects of Panax ginseng Berry Polysaccharides via Activation of Immune-Related Cells.

Authors:  Dae-Young Lee; Chan Woong Park; Sue Jung Lee; Hye-Ryung Park; Su Hwan Kim; Seung-U Son; Jiyong Park; Kwang-Soon Shin
Journal:  Front Pharmacol       Date:  2019-11-26       Impact factor: 5.810

Review 7.  Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases.

Authors:  Hai Liu; Jianqiong Yang; Wanqing Yang; Shaonan Hu; Yali Wu; Bo Zhao; Haiyan Hu; Shouying Du
Journal:  Drug Des Devel Ther       Date:  2020-02-07       Impact factor: 4.162

8.  Notoginsenoside R1 counteracts mesenchymal stem cell-evoked oncogenesis and doxorubicin resistance in osteosarcoma cells by blocking IL-6 secretion-induced JAK2/STAT3 signaling.

Authors:  Minan Lu; Kegong Xie; Xianzhe Lu; Lu Lu; Yu Shi; Yujin Tang
Journal:  Invest New Drugs       Date:  2020-10-30       Impact factor: 3.850

Review 9.  Therapeutic Potential and Cellular Mechanisms of Panax Notoginseng on Prevention of Aging and Cell Senescence-Associated Diseases.

Authors:  Haiping Zhao; Ziping Han; Guangwen Li; Sijia Zhang; Yumin Luo
Journal:  Aging Dis       Date:  2017-12-01       Impact factor: 6.745

10.  Notoginsenoside R1 Protects Against Diabetic Cardiomyopathy Through Activating Estrogen Receptor α and Its Downstream Signaling.

Authors:  Bin Zhang; Jingyi Zhang; Chenyang Zhang; Xuelian Zhang; Jingxue Ye; Shihuan Kuang; Guibo Sun; Xiaobo Sun
Journal:  Front Pharmacol       Date:  2018-11-02       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.